Merck & Co wins another US Fosamax bellwether case
This article was originally published in Scrip
Executive Summary
Merck & Co has picked up another win in a so-called bellwether case where an individual has alleged in a product liability suit that the bisphosphonate Fosamax (alendronate) caused jaw necrosis. Merck has now won three of the first four bellwether cases in the litigation – with the cases generally alleging that Fosamax can cause osteonecrosis of the jaw and that Merck failed to properly warn of the risk.